Mizoram records first COVID-19 fatality as India tally nears 80 lakh; active cases below 7 lakh for sixth day
Meanwhile, the Delhi government announced that schools will remain closed till further orders, and the DGCA extended the suspension of international passenger flights till 30 November
Cipla confirms collaboration with CSIR, IICT, ICMR to develop COVID-19 treatment
The Mumbai-based firm is also ramping up manufacturing of drugs required to treat COVID-19, like Lopinavir-Ritonavir and Hydroxychloroquine
Cipla's remdevisir to cost Rs 4,000 per 100 mg vial in India; pricing among lowest globally: Report
Cipla India business chief executive officer Nikhil Chopra said that the company was launching Cipremi commercially on Wednesday and aims to supply over 80,000 vials within the first month, but did not give details on pricing.
Health
Mylan's remdesivir to cost Rs 4,800 per 100 mg vial in India, 80% cheaper than price tag in wealthy nations
Gilead priced remdesivir at $2,340 per patient for rich nations and agreed to send nearly all of its supply of the drug to the United States over the next three months
Sensex drops 260 points, Nifty settles below 9,050-mark at close of trading session; banking, financial stocks drag
Sensex tumbled 260 points on Friday, dragged by losses in banking and financial stocks as RBI's rate cut and other measures to prop up the economy failed to meet market expectations.
Cipla submits application with USFDA for generic version of asthma drug
Drug major Cipla on Monday said it has submitted an application with the US health regulator for a generic version of GSK's Advair Diskus, which is used in the treatment of asthma and other respiratory disorders
Sensex plunges over 800 points, Nifty slumps 227 points in early trade as economic package fails to impress
After hitting a low of 30,265.67, the Sensex was trading 731.91 points or 2.35 percent lower at 30,365.82. Similarly, NSE Nifty slumped 226.90 points, or 2.48 percent, to 8,909.95.
Cipla inks licensing pact with Gilead Sciences for potential COVID-19 treatment drug remdesivir
Homegrown pharma major Cipla Ltd on Wednesday said it has signed a non-exclusive licensing agreement with Gilead Sciences Inc for manufacturing and distribution of investigational drug remdesivir, a potential therapy for COVID-19
Hetero inks licensing agreement with Gilead for manufacturing, distribution of remdesivir
Domestic pharma major Hetero on Wednesday said it has entered into a licensing agreement with Gilead Sciences Inc for manufacturing and distribution of remdesivir, a potential therapy for COVID-19
Gilead ties up with 5 generic drugmakers in India, Pakistan for COVID-19 drug supply; licensees to set price for product
Gilead’s antiviral drug remdesivir earlier this month received the US Food and Drug Administration’s emergency use authorization to treat COVID-19 patients.
Markets end in red: Sensex plummets 2,002 points, Nifty suffers heavy loss of over 560 points; ICICI Bank top loser
Sensex plunged 5.94 percent or 2,002 points on Monday, tracking massive selloffs in global markets amid rising US-China tensions.
Markets end week with gain of 7%: Sensex soars 997 points to end at 33,717, Nifty surges to 9,860; Tata Motors, ONGC major gainers
The NSE Nifty 50 index ended 3.2 percent higher at 9,859. The index was up 7.7 percent this week.
Bears grip markets after two sessions of bullish show: Sensex, Nifty end on negative note; all sectoral indices close in red
Sensex, Nifty end on negative note after a volatile session on 24 April
Stock Market Today Latest Updates: Market at 3-week high as Sensex soars over 1,200 points, Nifty above 9,100; M&M zooms nearly 17%
Stock Market Today LIVE Updates: Bourses erase early gains; Sensex slips 250 points, Nifty below 9,000-mark; bank stocks in green
Bourses track Asian peers: Sensex rallies over 900 points, Nifty reclaims 9,000-mark; HDFC, Maruti among top gainers
After hitting a high of 30,847.10, the 30-share Sensex was trading 925.67 points or 3.10 per cent higher at 30,819.63.
Sensex up over 100 points, Nifty rises after markets open in green post-Narendra Modi's 21-day nation-wide lockout announcement
Sensex was up 353.09 points or 1.32 percent at 27027.12, and the Nifty up 97.55 points or 1.25% at 7898.60. About 243 shares have advanced, 348 shares declined, and 35 shares are unchanged.
Sensex jumps over 200 points, Nifty above 7600-level; Infosys, HUL stocks up 6%
At 10.02, the indices erases all its early gains and slipped in to red with Nifty below 7,700-mark.
Coronavirus outbreak: Govt restrains exports of a few APIs, formulations; lists essential medicines that could run out of stock
In a notification, the government put curbs on the exports of certain APIs and formulations, including Paracetamol, Vitamin B1 and B12 amid the coronavirus outbreak claimed over 3,000 lives across the world.
Real bank credit growth drops drastically, UTI AMC IPO could not have been better timed; all this and more on Moneycontrol Pro
Despite the loan melas and multiple rate cuts, bank credit continues to remain sluggish.
Can Bank Nifty's outperformance sustain, time to remodel food procurement policy; all this and more on Moneycontrol Pro
The Bank Nifty has been a stellar outperformer in the past one year.